TICKERNERD
Menu
MGRXMGRXHealthcare · Health Information Services

MGRX Stock Forecast: Mangoceuticals, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$0.38
−9.15% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 12 Oct 2026 — in the lower half.

Market cap
$9.1M
Ticker Nerd rank
40 / 100
Median analyst target
—
Analysts covering
—
Revenue$69K−59.1% y/y
Operating income−$1.0M
Net income−$1.3M
Free cash flow−$261K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.3%
1M
−4.9%
YTD
−48.2%
1Y
−82.6%
From 52W high
−86.0%
From 52W low
+136.7%
$0.16
$2.74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MGRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mangoceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Size
93
Growth
69
Issuance
43
Volatility
35
Quality
33
Revisions
25
Momentum
23
Value
19

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (19): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MGRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00$2.50Jan 26Apr 26Jul 26Oct 26MGRX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MGRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Mangoceuticals, Inc. returned −82.6% against +20.4% for the S&P 500, dividends included.

MGRX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26MGRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MGRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Mangoceuticals, Inc. (MGRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
28.2×

Cheaper than 7% of US stocks

Price / book
0.6×

Cheaper than 82% of US stocks

EV / EBITDA
−0.8×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
−59.1%

Higher than 4% of US stocks

Earnings growth (YoY)
−59.1%

Higher than 9% of US stocks

Gross margin
64.3%

Higher than 77% of US stocks

Operating margin
−1502.5%

Higher than 5% of US stocks

Net margin
54.9%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−95.1%

Higher than 14% of US stocks

Return on assets
−47.0%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mangoceuticals, Inc. (MGRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mangoceuticals, Inc. has a market value of $9.1M and an enterprise value of $9.4M.

  • Revenue in the twelve months to 30 June 2026: $315K. The latest quarter shrank 59.1% year on year.

  • Net income over the same four quarters: −$15.1M, a −4791.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$3.9M.

  • Shares outstanding: 17.2M.

  • Trailing P/E: −0.2×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Mangoceuticals, Inc. employs 3 people — $105K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Oct 2026

Data provided by Twelve Data

Peers

MGRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
MGRXMangoceuticals, Inc.$9.1M
40
ACONAclarion, Inc.$6.5M
29
HCTIHealthcare Triangle, Inc.$6.5M
22
BFRGBullFrog AI Holdings, Inc.$10.8M
53
ZCMDZhongchao, Inc.$6.2M
23
MNDRMobile-health Network Solutions$3.6M
13
ONMDOneMedNet Corp.$23.6M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mangoceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MGRX news & analysis

Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

GlobeNewsWire · 1 Oct 2026positive

Mangoceuticals announced a $2.5 million strategic investment in its subsidiary MangoRx IP Holdings, with an initial $1.75 million tranche received. The subsidiary-level investment provides capital to advance commercialization of the company's antiviral intellectual property portfolio without issuing MGRX common stock.

Why it matters — MGRX watchers would care because the investment funds commercialization of the company's antiviral IP portfolio while avoiding dilution of existing shareholders' common stock.

MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 17 Aug 2026negative

Halper Sadeh LLC, an investor rights law firm, announced it is investigating the merger of Mangoceuticals, Inc. and Nuclea Energy Inc., looking into whether Mangoceuticals and its board violated federal securities laws regarding the fairness of the price paid to shareholders. The firm is inviting Mangoceuticals shareholders to learn about their rights and options.

Why it matters — The investigation raises potential concerns about the terms and board conduct in MGRX's pending merger with Nuclea Energy for shareholders.

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

Newsfile Corp · 13 Aug 2026neutral

Nuclea Energy has entered into a definitive agreement to acquire Moltex Energy's advanced nuclear technology assets, including intellectual property and development materials related to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

Why it matters — Mangoceuticals (MGRX) watchers may note this as a separate industry development involving nuclear technology assets, though the news does not directly mention MGRX.

Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

GlobeNewsWire · 13 Aug 2026positive

Mangoceuticals Inc.'s merger partner, Nuclea Energy, has entered a definitive agreement to acquire Moltex Energy's advanced nuclear technology assets, including SSR-W advanced reactor and WATSS spent fuel recycling technologies, backed by over C$96 million in funding.

Why it matters — For MGRX watchers, this development strengthens Nuclea Energy's technology portfolio and funding base ahead of the planned merger with Mangoceuticals.

Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

Newsfile Corp · 6 Aug 2026positive

Nuclea Energy Inc. announced it has signed a non-binding memorandum of understanding with New Mining Co. to evaluate the technical and structural feasibility of deploying Nuclea's modular reactor technology to serve New Mining's behind-the-meter power needs. The evaluation follows a phased path toward a cumulative 100 MWe of behind-the-meter capacity for New Mining's high-density data center operations.

Why it matters — For MGRX watchers, this development signals potential progress in Nuclea Energy's modular reactor commercialization and its fit for behind-the-meter high-density computing applications.

FAQ

Frequently asked questions about MGRX stock

How does Ticker Nerd's model rank MGRX?

As at 12 Oct 2026, Mangoceuticals, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

What is the MGRX stock forecast for 2030?

No analyst covering Mangoceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGRX are extrapolating price history, which says nothing about the business.

How has MGRX stock performed over the past year?

Mangoceuticals, Inc. returned -82.6% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mangoceuticals, Inc. do?

Mangoceuticals, Inc. is a healthcare company focused on men’s wellness products and services delivered through a telemedicine platform.

What is the latest news on MGRX?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche". Mangoceuticals announced a $2.5 million strategic investment in its subsidiary MangoRx IP Holdings, with an initial $1.75 million tranche received. The subsidiary-level investment provides capital to advance commercialization of the company's antiviral intellectual property portfolio without issuing MGRX common stock.

Company

About Mangoceuticals, Inc.

Mangoceuticals, Inc. is a healthcare company focused on men’s wellness products and services delivered through a telemedicine platform. The company develops, markets, and sells a range of branded offerings that address erectile dysfunction, hair loss, hormone balance and therapy, and weight loss, alongside related online consultations and pharmacy fulfillment services. Its product portfolio includes Mango, Grow, Mojo, and Slim, which are designed for direct-to-consumer access through digital health channels. Mangoceuticals also provides prescribed medications through licensed pharmacy partners as part of its telehealth model, connecting patients with healthcare professionals for online care. Based in Dallas, Texas, and founded in 2021, Mangoceuticals operates in the healthcare services market with a focus on accessible, digitally enabled wellness solutions.

CEO Mr. Jacob D. Cohen · 3 employees · United States · https://www.mangoceuticals.com